CIP
PRCT icon

Champlain Investment Partners’s Procept Biorobotics PRCT Stock Holding History

Champlain Investment Partners’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.2M Sell
981,381
-154,941
-14% -$3.88M 0.57% 83
2026
Q1 		$28.4M Sell
1,136,322
-304,712
-21% -$8.59M 0.36% 95
2025
Q4 		$45.3M Buy
1,441,034
+3,137
+0.2% +$104K 0.46% 87
2025
Q3 		$51.3M Buy
1,437,897
+367,251
+34% +$16.8M 0.39% 102
2025
Q2 		$61.7M Buy
1,070,646
+394,450
+58% +$22.3M 0.43% 96
2025
Q1 		$39.4M Buy
676,196
+219,266
+48% +$15M 0.29% 122
2024
Q4 		$36.8M Sell
456,930
-193,363
-30% -$16.5M 0.23% 121
2024
Q3 		$52.1M Sell
650,293
-714,986
-52% -$50.8M 0.31% 104
2024
Q2 		$83.4M Sell
1,365,279
-207,030
-13% -$12.3M 0.51% 82
2024
Q1 		$77.7M Sell
1,572,309
-15,730
-1% -$749K 0.44% 89
2023
Q4 		$66.6M Buy
1,588,039
+19,645
+1% +$669K 0.39% 93
2023
Q3 		$51.5M Buy
+1,568,394
New +$53.5M 0.33% 103

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Champlain Investment Partners's PRCT Position: Q2 2026 in Review

Champlain Investment Partners reduced its Procept Biorobotics (PRCT) stake by 14% in Q2 2026, selling an estimated $3.88M and leaving 981,381 shares worth $22.2M. The position accounts for 0.57% of the portfolio, ranked #83.

Champlain Investment Partners first reported a position in PRCT in Q3 2023 and has held it in 12 quarters since. The position peaked at $83.4M in Q2 2024. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Champlain Investment Partners held 981,381 shares of Procept Biorobotics worth $22.2M as of Q2 2026.
  • Champlain Investment Partners sold 154,941 Procept Biorobotics shares in Q2 2026, an estimated $3.88M.
  • Procept Biorobotics made up 0.57% of Champlain Investment Partners's portfolio in Q2 2026, its #83 holding.
  • Champlain Investment Partners first reported a position in Procept Biorobotics in Q3 2023 and has held it in 12 quarters since.
  • Champlain Investment Partners's Procept Biorobotics position peaked at $83.4M in Q2 2024.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Champlain Investment Partners's 13F filing for Q2 2026, filed 12 Aug 2026.